The Predictive Factors of Arteriovenous Fistula Maturation in Patients with End-Stage Renal Disease

2020 ◽  
Vol 25 (1) ◽  
pp. 28-34
Author(s):  
Supomo Supomo ◽  
Satya Septia Wahyunigrum ◽  
Aditya Agam Nugraha

Highlights Arterial diameter above 2 mm had an almost 5 times better AVF maturation outcome. Average age of ESRD patients who underwent the AVF procedure was above 50 years. Percentage of AVF maturation was higher in men. Hypertension was the most common comorbid factor in ESRD patients.

2018 ◽  
Vol 37 (3) ◽  
pp. 277-286 ◽  
Author(s):  
Muhammad A. Siddiqui ◽  
Suhel Ashraff ◽  
Derek Santos ◽  
Robert Rush ◽  
Thomas Carline ◽  
...  

Author(s):  
Putie Hapsari ◽  
Teguh Marfen Djajakusumah ◽  
Zacky Fauzie ◽  
Muhammad Faiz Ulurrosyad

Introduction: Patients with end stage renal disease require hemodialysis. Radiocephalic arteriovenous fistula is the main choice of vascular access in patients who undergo hemodialysis procedure. Physiological vein distensibility is an important aspect in forming a mature arteriovenous fistula. This study aims to analyze the correlation between preoperative distensibility and arteriovenous fistula maturation. Method: Data are collected from end stage renal disease patients in Hasan Sadikin Hospital and RA Habibie Hospitals that will go through radiocephalic arteriovenous fistula procedure during the period of October 2018 to February 2019. Vein distension procedure is performed before the operation and maturation is evaluated four to six weeks after the operation. The comparison of preoperative venous distensibility in two different groups of arteriovenous fistula maturation category is analyzed using chi square test model. Result: This study found that preoperative venous distensibility value affects arteriovenous fistula maturation with a statistical significance (p-value = 0.007), yielding a contingency coefficient of 0.553, and a very strong relation value of 0.782. Conclusion: Preoperative vein distensibility of more than 30% is predictive of successful arteriovenous maturation.


2020 ◽  
Vol 62 ◽  
pp. 304-309
Author(s):  
Gustavo Martinez-Mier ◽  
Cecilia Camargo-Diaz ◽  
Marco Antonio Urbina-Velazquez ◽  
Sandro Fabricio Avila-Pardo

2019 ◽  
Vol 41 (2) ◽  
pp. 185-192 ◽  
Author(s):  
Reza Manani ◽  
Gholamreza Kazemzadeh ◽  
Ali Saberi ◽  
Fatemeh Sadeghipour ◽  
Asghar Rahmani

Abstract Background: Arteriovenous fistula (AVF) maturation is one of the main concerns in patients with end-stage renal disease (ESRD) and finding a strategy for increasing success rate and accelerating fistula maturation is valuable. The aim of this study was to evaluate the effects of papaverine injection on AVF maturation and success rate. Method: This study was a randomized clinical trial that involved 110 patients with ESRD that were referred for AVF construction. Patients were allocated in papaverine group and control group with block randomization according to age and sex. In the case group, papaverine (0.1 or 0.2 cc) was injected locally within the subadventitia of artery and vein after proximal and distal control during AVF construction and in the control group, AVF construction was done routinely without papaverine injection. Results: Maturation time in case and control groups was 37.94 ± 11.49 and 44.23 ± 9.57 days, respectively (p=0.004). Hematoma was not seen in the case group but occurred in one patient in the control group. One patient of the case group developed venous hypertension. Four functional fistulas, 1 (1.8%) in the case group and 3 (5.5%) in the control group, failed to mature (p=0.618). Maturation rate did not differ between the two groups statistically (p=0.101). Conclusion: Local papaverine injection increased vessel diameter and blood flow, increasing shearing stress in both arterial and venous segment of recently created AVF. In this way, papaverine probably can decrease AVF maturation time without an increase in complications.


2017 ◽  
Vol 37 (6) ◽  
pp. 658-661 ◽  
Author(s):  
Nosratollah Nezakatgoo ◽  
Albert Ndzengue ◽  
Manhunath Ramaiah ◽  
Elvira O. Gosmanova

Peritoneal dialysis (PD) interruption requiring hemodialysis (HD) is not uncommon and its frequently abrupt nature prevents timely creation of permanent HD access and avoidance of central venous catheters (CVC). We retrospectively studied a cohort of 24 end-stage renal disease (ESRD) patients (mean age 50.7 years, 83.3% African-Americans, 58.3% females, time on dialysis interquartile range [IQR] 0 - 65 days) who had simultaneous PD catheter insertion and backup arteriovenous fistula (AVF) creation between January 1, 2012, and December 31, 2013. The primary outcome of interest was the percent of patients receiving HD through the backup AVF at the time of PD interruption. A median (IQR) for PD catheter use after its insertion was 10.5 (2 - 20) days. After the mean follow-up of 19.6 months, 12 patients remained on PD, 2 patients received a kidney transplant, and 1 patient died. The overall AVF patency was 66.7%. A total of 9 (37.5%) patients had PD interruption requiring permanent (8 patients) or temporary (1 patient) HD after the mean (standard deviation [SD]) follow-up of 12.3 (8.2) months. Arteriovenous fistula was used as the initial access in 4 patients, and in 3 patients the original AVF was used after additional surgical revision. Forty-four percent of patients with a backup AVF fistula avoided CVC at the time of PD interruption requiring HD. The simultaneous AVF creation at the time of PD catheter insertion reduced but did not fully eliminate CVC at the time of PD interruption. Larger studies are needed to evaluate the utility of a backup AVF in PD patients.


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Morwan Bahi

The formation of the arteriovenous fistula is an important method of vascular access for patients with end-stage renal disease (ESRD). This allows renal filtration resulting in improved life quality and expectancy for ESRD patients. The biggest drawback to arteriovenous fistula formation is thrombosis, which can occur at an early or delayed stage. One suggested method of reducing postoperative arteriovenous fistula thrombosis rates is the administration of intraoperative systemic heparin. Heparin use in this context is debated, and there is currently no consensus on its use. There are a number of small randomised control studies trialling use of heparin but no large systematic trials. In this report, we collate existing evidence in the form of a review article and attempt to extrapolate a consensus of the evidence.


2018 ◽  
Vol 91 (4) ◽  
pp. 399-407
Author(s):  
Alexandru Oprea ◽  
Adrian Molnar ◽  
Dan Vlăduțiu ◽  
Traian Scridon ◽  
Cătălin Trifan ◽  
...  

Background and aims: Arteriovenous fistula (AVF) maturation failure rates remain high in patients with end-stage renal disease (ESRD). Although preoperative morphological and functional assessment of blood vessels by duplex ultrasonography (DUS) has been shown to improve AVF maturation, there is no consensus regarding the optimal vein (VD) and artery (AD) diameters to be universally used for AVF creation. To improve patient selection, set out to investigate if there is a correlation between preoperative VD/AD and clinical covariates, and postoperative AVF outcome.Methods: This was a prospective cohort study conducted during January–August 2014. ESRD patients referred to “Niculae Stăncioiu” Heart Institute Cluj-Napoca, who had a VD ≥1.9 mm and AD ≥1.5 mm, as measured by DUS, and underwent AVF creation were enrolled. We assessed whether preoperative VD/AD and clinical covariates were associated with AVF maturation rate and primary patency at 2 years after AVF creation.Results: Of 115 patients referred for AVF creation, 93 were included in the study. Mean (± standard deviation) VD was 3.3 ± 1.1 mm and VDs were distributed in quartile Q1 <2.55 mm, Q2: 2.56-3.10 mm, Q3: 3.11-3.70 mm and Q4: >3.71 mm. Mean AD was 3.3 ± 1.4 mm and ADs were distributed in Q1 <2.55 mm, Q2: 2.56-3.10 mm, Q3: 3.11-3.70 mm, and Q4, >3.71 mm. AVF maturation rate increased proportionally with VD from Q1 (62%) to Q2 (70%), Q3 (82%) to Q4 (96%) (p=0.03). Based on AD, a higher AVF maturation rate was observed in Q3 (86%), Q4 (83%) vs Q1 (71%) and Q2 (67%). Long-term primary patency of AVFs seemed not to be influenced by VD and AD. In older patients and those with peripheral arterial disease, AVF maturation failure tended to be higher.Conclusions: Our findings suggest that a preoperative VD ≥1.9 mm and AD ≥1.5 mm have a successful maturation rate of AVF greater than 60% in ESRD patients. The maturation rate of surgical AVF increases proportionally with the size of VD used for AVF creation.


2014 ◽  
Vol 7 (1) ◽  
pp. 22-25
Author(s):  
Timmy Lee

The vascular access serves as the “lifeline” for the hemodialysis patient, but in recent years has become the “Achilles Heel” of the hemodialysis procedure. The vascular health of the vessels used to create arteriovenous accesses is paramount to vascular access maturation and successful outcomes. Vascular calcification is widely present in the vessels of chronic kidney disease (CKD) and end stage renal disease (ESRD) patients, and may also potentially impact the vascular access remodeling process. Few studies have been published to date evaluating vascular calcification as it relates to vascular access outcomes. However, an improved understanding of how vascular calcification plays a pathophysiological role in hemodialysis vascular access dysfunction may improve therapies to treat arteriovenous fistula (AVF) non-maturation and the health of the vessels prior to vascular access creation.


Sign in / Sign up

Export Citation Format

Share Document